MARKET

AKTX

AKTX

Akari
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.930
-0.310
-9.57%
After Hours: 2.920 -0.01 -0.34% 17:49 01/21 EST
OPEN
3.270
PREV CLOSE
3.240
HIGH
3.300
LOW
2.900
VOLUME
434.61K
TURNOVER
--
52 WEEK HIGH
3.760
52 WEEK LOW
0.8700
MARKET CAP
112.73M
P/E (TTM)
-4.0137
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 10h ago
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 1d ago
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced t...
GlobeNewswire · 01/06 14:32
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leuko...
GlobeNewswire · 01/06 14:32
Akari Therapeutics reports Q3 results
Akari Therapeutics ([[AKTX]] +2.1%) GAAP EPS of $0.00Cash of ~$12.3M vs. $5.7M.Press Release
Seekingalpha · 12/11/2020 16:35
Akari Therapeutics updates trial progress; returns to profitability
Akari Therapeutics (AKTX) records the first quarterly net income in nearly five years as the company announces financial results for Q3 2020.Recording ~$1.4M of net income (compared to a net loss of
Seekingalpha · 12/11/2020 15:32
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
-- Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) meetings earlier in the year.
GlobeNewswire · 12/11/2020 14:00
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
* Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) meetings earlier in the year. ...
GlobeNewswire · 12/11/2020 14:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKTX. Analyze the recent business situations of Akari through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKTX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 2.39M
% Owned: 6.21%
Shares Outstanding: 38.47M
TypeInstitutionsShares
Increased
2
43.25K
New
11
-41.60K
Decreased
5
1.45M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.04%
Pharmaceuticals & Medical Research
-0.53%
Key Executives
Chairman/Director
Ray Prudo
Chief Executive Officer
David Solomon
Chief Financial Officer
Torsten Hombeck
Chief Operating Officer/Director
Clive Richardson
Vice President
Nigel Hernandez
Director
David Byrne
Director
Peter Feldschreiber
Director
Michael Grissinger
Director
Robert Ward
Director
Donald Williams
Non-Executive Director
James Hill
Non-Executive Director
Stuart Ungar
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AKTX
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4, or LTB4. It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement.
More

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.